Clinical Trial Update: Predictive Signature of Benralizumab Response [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating a predictive biomarker signature for benralizumab response in eosinophilic asthma with severe features; recruitment is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Asthma

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Sponsor: Nantes University Hospital | Conditions: Asthma; Eosinophilic, Severe Asthma | Phase 4 | Status: RECRUITING